Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation

by Alberts, M., Angiolillo, D.J, Bhatt, D.L, Deliargyris, E.N, Kimmelstiel, C., Mehran, R., Prats, J., Rosengart, T., Scheiman, J., Schneider, D.J, Steg, P.G
Published 2022

Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating re...

by Cutlip, D.E, Deliargyris, E.N, Doros, G., Gibson, C.M, Kroger, H., Lee, V.T, Mack, M.J, Ohman, E.M, Schneider, D.J, Sellke, F.W, Thourani, V.H
Published 2022

Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION

by Bhatt, D.L, Deliargyris, E.N, Gibson, C.M, Hamm, C.W, Harrington, R.A, Leonardi, S., Lopes, R.D, Mahaffey, K.W, Peterson, B.E, Prats, J., Price, M.J, Steg, P.G, Stone, G.W, White, H.D
Published 2022

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

by Bhatt, D.L, Cavender, M.A, CHAMPION PHOENIX Investigators*, Deliargyris, E.N, Gibson, C.M, Hamm, C.W, Harrington, R.A, Leonardi, S., Lopes, R.D, Mahaffey, K.W, Prats, J., Price, M.J, Steg, P.G, Stone, G.W, White, H.D
Published 2022